|
1
|
Frey N and Olson EN: Cardiac hypertrophy:
The good, the bad, and the ugly. Annu Rev Physiol. 65:45–79.
2003.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Horton JS, Shiraishi T, Alfulaij N,
Small-Howard AL, Turner HC, Kurokawa T, Mori Y and Stokes AJ:
‘TRPV1 is a component of the atrial natriuretic signaling complex,
and using orally delivered antagonists, presents a valid
therapeutic target in the longitudinal reversal and treatment of
cardiac hypertrophy and heart failure’. Channels (Austin). 13:1–16.
2019.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Patten RD and Hall-Porter MR: Small animal
models of heart failure: Development of novel therapies, past and
present. Circ Heart Fail. 2:138–144. 2009.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Huang L, Xi Z, Wang C, Zhang Y, Yang Z,
Zhang S, Chen Y and Zuo Z: Phenanthrene exposure induces cardiac
hypertrophy via reducing miR-133a expression by DNA methylation.
Sci Rep. 6(20105)2016.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Spänig S, Kellermann K, Dieterlen MT,
Noack T, Lehmann S, Borger MA, Garbade J, Barac YD and Emrich F:
The ubiquitin proteasome system in ischemic and dilated
cardiomyopathy. Int J Mol Sci. 20(6354)2019.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Lino CA, Demasi M and Barreto-Chaves ML:
Ubiquitin proteasome system (UPS) activation in the cardiac
hypertrophy of hyperthyroidism. Mol Cell Endocrinol.
493(110451)2019.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Cacciapuoti F: Role of
ubiquitin-proteasome system (UPS) in left ventricular hypertrophy
(LVH). Am J Cardiovasc Dis. 4:1–5. 2014.PubMed/NCBI
|
|
8
|
Cui X, Zhang Y, Wang Z, Yu J, Kong Z and
Ružić L: High-intensity interval training changes the expression of
muscle RING-finger protein-1 and muscle atrophy F-box proteins and
proteins involved in the mechanistic target of rapamycin pathway
and autophagy in rat skeletal muscle. Exp Physiol. 104:1505–1517.
2019.PubMed/NCBI View
Article : Google Scholar
|
|
9
|
Usui S, Chikata A, Takatori O, Takashima
SI, Inoue O, Kato T, Murai H, Furusho H, Nomura A, Zablocki D, et
al: Endogenous muscle atrophy F-box is involved in the development
of cardiac rupture after myocardial infarction. J Mol Cell Cardiol.
126:1–12. 2019.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Gupta I, Varshney NK and Khan S: Emergence
of members of TRAF and DUB of ubiquitin proteasome system in the
regulation of hypertrophic cardiomyopathy. Front Genet.
9(336)2018.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Marshall SM: 60 years of metformin use: A
glance at the past and a look to the future. Diabetologia.
60:1561–1565. 2017.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Markowicz-Piasecka M, Huttunen KM,
Mateusiak L, Mikiciuk-Olasik E and Sikora J: Is Metformin a Perfect
Drug? Updates in Pharmacokinetics and Pharmacodynamics. Curr Pharm
Des. 23:2532–2550. 2017.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Driver C, Bamitale KDS, Kazi A, Olla M,
Nyane NA and Owira PMO: Cardioprotective Effects of Metformin. J
Cardiovasc Pharmacol. 72:121–127. 2018.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Tseng YT: Cardioprotective effect of
metformin against doxorubicin cardiotoxicity in rats. Anatol J
Cardiol. 16:242–243. 2016.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Polianskyte-Prause Z, Tolvanen TA,
Lindfors S, Dumont V, Van M, Wang H, Dash SN, Berg M, Naams JB,
Hautala LC, et al: Metformin increases glucose uptake and acts
renoprotectively by reducing SHIP2 activity. FASEB J. 33:2858–2869.
2019.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Tsai CH, Tsai HC, Huang HN, Hung CH, Hsu
CJ, Fong YC, Hsu HC, Huang YL and Tang CH: Resistin promotes tumor
metastasis by down-regulation of miR-519d through the AMPK/p38
signaling pathway in human chondrosarcoma cells. Oncotarget.
6:258–270. 2015.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Sun Y, Liang X, Chen J, Tang R, Li L and
Li D: Change in Ubiquitin Proteasome System of Grass Carp
Ctenopharyngodon idellus Reared in the Different Stocking
Densities. Front Physiol. 9(837)2018.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Menconi M, Gonnella P, Petkova V, Lecker S
and Hasselgren PO: Dexamethasone and corticosterone induce similar,
but not identical, muscle wasting responses in cultured L6 and
C2C12 myotubes. J Cell Biochem. 105:353–364. 2008.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Willis MS, Ike C, Li L, Wang DZ, Glass DJ
and Patterson C: Muscle ring finger 1, but not muscle ring finger
2, regulates cardiac hypertrophy in vivo. Circ Res. 100:456–459.
2007.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Arya R, Kedar V, Hwang JR, McDonough H, Li
HH, Taylor J and Patterson C: Muscle ring finger protein-1 inhibits
PKC{epsilon} activation and prevents cardiomyocyte hypertrophy. J
Cell Biol. 167:1147–1159. 2004.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Conraads VM, Vrints CJ, Rodrigus IE,
Hoymans VY, Van Craenenbroeck EM, Bosmans J, Claeys MJ, Van Herck
P, Linke A, Schuler G, et al: Depressed expression of MuRF1 and
MAFbx in areas remote of recent myocardial infarction: A mechanism
contributing to myocardial remodeling? Basic Res Cardiol.
105:219–226. 2010.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Bodine SC, Latres E, Baumhueter S, Lai VK,
Nunez L, Clarke BA, Poueymirou WT, Panaro FJ, Na E, Dharmarajan K,
et al: Identification of ubiquitin ligases required for skeletal
muscle atrophy. Science. 294:1704–1708. 2001.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Fielitz J, Kim MS, Shelton JM, Latif S,
Spencer JA, Glass DJ, Richardson JA, Bassel-Duby R and Olson EN:
Myosin accumulation and striated muscle myopathy result from the
loss of muscle RING finger 1 and 3. J Clin Invest. 117:2486–2495.
2007.PubMed/NCBI View
Article : Google Scholar
|
|
24
|
Shaalan WM, El-Hameid NAA, El-Serafy SS
and Salem M: Expressions and characterization of MuRFs, Atrogin-1,
F-box25 genes in tilapia, Oreochromis niloticus, in response to
starvation. Fish Physiol Biochem. 45:1321–1330. 2019.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Nesti L and Natali A: Metformin effects on
the heart and the cardiovascular system: A review of experimental
and clinical data. Nutr Metab Cardiovasc Dis. 27:657–669.
2017.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Ying H, Xu MC, Tan JH, Shen JH, Wang H and
Zhang DF: Pressure overload-induced cardiac hypertrophy response
requires janus kinase 2-histone deacetylase 2 signaling. Int J Mol
Sci. 15:20240–20253. 2014.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Li J, Minćzuk K, Massey JC, Howell NL, Roy
RJ, Paul S, Patrie JT, Kramer CM, Epstein FH, Carey RM, et al:
Metformin Improves Cardiac Metabolism and Function, and Prevents
Left Ventricular Hypertrophy in Spontaneously Hypertensive Rats. J
Am Heart Assoc. 9(e015154)2020.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Mohan M, Al-Talabany S, McKinnie A, Mordi
IR, Singh JSS, Gandy SJ, Baig F, Hussain MS, Bhalraam U, Khan F, et
al: A randomized controlled trial of metformin on left ventricular
hypertrophy in patients with coronary artery disease without
diabetes: The MET-REMODEL trial. Eur Heart J. 40:3409–3417.
2019.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Rena G, Hardie DG and Pearson ER: The
mechanisms of action of metformin. Diabetologia. 60:1577–1585.
2017.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Yang F, Qin Y, Wang Y, Meng S, Xian H, Che
H, Lv J, Li Y, Yu Y, Bai Y, et al: Metformin inhibits the NLRP3
inflammasome via AMPK/mTOR-dependent effects in diabetic
cardiomyopathy. Int J Biol Sci. 15:1010–1019. 2019.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Xiao B, Sanders MJ, Carmena D, Bright NJ,
Haire LF, Underwood E, Patel BR, Heath RB, Walker PA, Hallen S, et
al: Structural basis of AMPK regulation by small molecule
activators. Nat Commun. 4(3017)2013.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Benes J, Kazdova L, Drahota Z, Houstek J,
Medrikova D, Kopecky J, Kovarova N, Vrbacky M, Sedmera D, Strnad H,
et al: Effect of metformin therapy on cardiac function and survival
in a volume-overload model of heart failure in rats. Clin Sci
(Lond). 121:29–41. 2011.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Witt CC, Witt SH, Lerche S, Labeit D, Back
W and Labeit S: Cooperative control of striated muscle mass and
metabolism by MuRF1 and MuRF2. EMBO J. 27:350–360. 2008.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Krawiec BJ, Nystrom GJ, Frost RA,
Jefferson LS and Lang CH: AMP-activated protein kinase agonists
increase mRNA content of the muscle-specific ubiquitin ligases
MAFbx and MuRF1 in C2C12 cells. Am J Physiol Endocrinol Metab.
292:E1555–E1567. 2007.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Thomson DM: The Role of AMPK in the
Regulation of Skeletal Muscle Size, Hypertrophy, and Regeneration.
Int J Mol Sci. 19(3125)2018.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Vilchinskaya NA, Krivoi II and Shenkman
BS: AMP-Activated Protein Kinase as a Key Trigger for the
Disuse-Induced Skeletal Muscle Remodeling. Int J Mol Sci.
19(3558)2018.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Chen B, Wu Q, Xiong Z, Ma Y, Yu S, Chen D,
Huang S and Dong Y: Adenosine monophosphate-activated protein
kinase attenuates cardiomyocyte hypertrophy through regulation of
FOXO3a/MAFbx signaling pathway. Acta Biochim Biophys Sin
(Shanghai). 48:827–832. 2016.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Chen BL, Ma YD, Meng RS, Xiong ZJ, Wang
HN, Zeng JY, Liu C and Dong YG: Activation of AMPK inhibits
cardiomyocyte hypertrophy by modulating of the FOXO1/MuRF1
signaling pathway in vitro. Acta Pharmacol Sin. 31:798–804.
2010.PubMed/NCBI View Article : Google Scholar
|
